Alpha 2.0
Login Register
» Authors » Andrea Varrone

Andrea Varrone

Explore the profile of Andrea Varrone including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 154
Citations 3602
Followers 0
Related Specialties
Nuclear Medicine
Radiology
Neurology
Top 10 Co-Authors
Christer Halldin
Lars Farde
Balazs Gulyas
Akihiro Takano
Anton Forsberg
Miklos Toth
Patrik Fazio
Flavio Nobili
Sangram Nag
Klaus Tatsch
Published In
Eur J Nucl Med Mol Imaging
J Nucl Med
EJNMMI Res
Mov Disord
Neuroimage
Affiliations
Soon will be listed here.
Recent Articles
1.
Correcting bias by accounting for radiotracer clearance in tissue: A validation study with [F]FE-PE2I PET in cross-sectional, test-retest and longitudinal cohorts
Oh M, Honhar P, Carson R, Hillmer A, Varrone A
J Cereb Blood Flow Metab . 2025 Feb; :271678X251322407. PMID: 39981611
Quantification of dopamine transporter (DAT) with [F]FE-PE2I PET is an important progression marker for Parkinson's disease (PD). This study aimed to validate a novel correction (c) for a less-biased estimate...
2.
Preserved Serotonin Transporter Availability in Parkinson Disease Measured with Either [C]MADAM or [C]DASB: A Study Including 2 Separate Cohorts of Nondepressed Patients
Oh M, Brumberg J, Sossi V, Varrone A
J Nucl Med . 2025 Jan; 66(2):309-314. PMID: 39746753
Serotonin transporter (SERT) availability was assessed using 2 tracers, [C],-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine ([C]DASB) and [C],-dimethyl-2-(2-amino-4-fluoromethylphenylthio)benzylamine) ([C]MADAM), in independent cohorts of patients and controls. This study aimed to independently confirm whether SERT remains...
3.
Identification and In Vitro and In Vivo Characterization of KAC-50.1 as a Potential α-Synuclein PET Radioligand
Saturnino Guarino D, Miranda Azpiazu P, Sunnemark D, Elmore C, Bergare J, Artelsmair M, et al.
ACS Chem Neurosci . 2024 Nov; 15(22):4210-4219. PMID: 39528351
The accumulation of aggregated α-synuclein (α-syn) is a pathological hallmark of Parkinson's disease (PD) and other synucleinopathies. Here within, we report the in vitro characterization targeting site 2 of α-syn...
4.
Spinocerebellar ataxia type 4 is caused by a GGC expansion in the ZFHX3 gene and is associated with prominent dysautonomia and motor neuron signs
Paucar M, Nilsson D, Engvall M, Laffita-Mesa J, Soderhall C, Skorpil M, et al.
J Intern Med . 2024 Jul; 296(3):234-248. PMID: 38973251
Background: Spinocerebellar ataxia 4 (SCA4), characterized in 1996, features adult-onset ataxia, polyneuropathy, and linkage to chromosome 16q22.1; its underlying mutation has remained elusive. Objective: To explore the radiological and neuropathological...
5.
Exploring the Interactions between two Ligands, UCB-J and UCB-F, and Synaptic Vesicle Glycoprotein 2 Isoforms
Li J, Zou R, Varrone A, Nag S, Halldin C, Agren H
ACS Chem Neurosci . 2024 May; 15(10):2018-2027. PMID: 38701380
modeling was applied to study the efficiency of two ligands, namely, and , to bind to isoforms of the synaptic vesicle glycoprotein 2 (SV2) that are involved in the regulation...
6.
Microsome Mediated in Vitro Metabolism: A Convenient Method for the Preparation of the PET Radioligand Metabolite [F]FE-PE2I-OH for Translational Dopamine Transporter Imaging
Schou M, Amini N, Takano A, Arakawa R, Dahl K, Toth M, et al.
ACS Chem Neurosci . 2023 Sep; 14(20):3732-3736. PMID: 37753876
Undesired radiometabolites can be detrimental to the development of positron emission tomography (PET) radioligands. Methods for quantifying radioligand metabolites in brain tissue include ex vivo studies in small animals or...
7.
Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial
Huttunen H, Booms S, Sjogren M, Kerstens V, Johansson J, Holmnas R, et al.
Mov Disord . 2023 May; 38(7):1209-1222. PMID: 37212361
Background: Cerebral dopamine neurotrophic factor (CDNF) is an unconventional neurotrophic factor that protects dopamine neurons and improves motor function in animal models of Parkinson's disease (PD). Objective: The primary objectives...
8.
[F]FE-PE2I DAT correlates with Parkinson's disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study
Kerstens V, Fazio P, Sundgren M, Halldin C, Svenningsson P, Varrone A
EJNMMI Res . 2023 Apr; 13(1):29. PMID: 37017878
Background: Correlations between dopamine transporter (DAT) availability and Parkinson's disease (PD) motor symptoms vary depending on the imaging modality, choice of regions of interest and clinical measures. We aimed to...
9.
Striatal dopamine transporter and receptor availability correlate with relative cerebral blood flow measured with [C]PE2I, [F]FE-PE2I and [C]raclopride PET in healthy individuals
Jonasson M, Frick A, Fazio P, Hjorth O, Danfors T, Axelsson J, et al.
J Cereb Blood Flow Metab . 2023 Mar; 43(7):1206-1215. PMID: 36912083
The aim of this retrospective study was to investigate relationships between relative cerebral blood flow and striatal dopamine transporter and dopamine D2/3 availability in healthy subjects. The data comprised dynamic...
10.
Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study
Ekman S, Cselenyi Z, Varrone A, Jucaite A, Martin H, Schou M, et al.
Clin Transl Sci . 2023 Feb; 16(6):955-965. PMID: 36808835
Brain metastases (BMs) are associated with poor prognosis in epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). Osimertinib is a third-generation, irreversible, EGFR-tyrosine kinase inhibitor that potently...